REG - Adv Medical Solutns. - Annual Report, Notice of AGM and Board Change

Advanced Medical SolutionsAnnouncement

29/04/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220429:nRSc9541Ja&default-theme=true

RNS Number : 9541J  Advanced Medical Solutions Grp PLC  29 April 2022

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Annual Report, Notice of Annual General Meeting and Board Change

 

 

Winsford, UK - 29 April 2022: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies, announces that
the Annual Report and Accounts for the year ended 31 December 2021 and Notice
of Annual General Meeting were posted to shareholders today and are available
on the Investor Relations section of the Group's website.

 

Annual General Meeting

The Board continues to monitor the COVID-19 pandemic and our priority at this
time remains the health, safety and wellbeing of all of our stakeholders. We
are delighted that, at the time of issuing this Notice, we will be able to
hold the AGM with no COVID-19 restrictions. However, the Board recognises that
the COVID-19 pandemic is an evolving situation and that it may be necessary to
modify our AGM arrangements. The arrangements are therefore subject to change,
including at short notice, if circumstances and/or public health guidance
changes.

 

The Board therefore recommends that you monitor the Company's announcements
for any updates and register to receive our RNS alerts at www.admedsol.com/
investor-relations/alert-service.

 

The Notice of Annual General Meeting and proxy forms were posted to
shareholders today and are available on the Group's website at
www.admedsol.com/investor-relations
(http://www.admedsol.com/investor-relations) . The AGM will be convened with
the minimum necessary quorum of two shareholders. The outcome of the
resolutions will as usual be determined by shareholder vote based on the proxy
votes received.

 

Shareholders are strongly encouraged to vote by proxy on the resolutions
contained in the AGM Notice and to appoint the "Chairman of the Meeting" as
their proxy, providing instructions on how the Chair should vote on the
proposed resolutions. This will ensure that your votes will be counted if you
(or any other proxy who you might otherwise appoint) choose not to attend the
AGM in person.

 

To ensure votes are counted at the AGM, completed proxy forms should be
returned to: Link Group, PXS, 10th Floor, Central Square, 29 Wellington
Street, Leeds, LS1 4DL and must be received by     11:00 am on 6 June 2022
in order to be valid. This is particularly important given potential delays
due to the continued impact of COVID-19, which could potentially cause delays
to the collection and delivery of postal services. Any shareholder who wishes
to attend the AGM in person is asked to register their intention to do so as
soon as practicable.

 

The results of the AGM will be announced to the London Stock Exchange and
placed on the Group's website, in the usual way, as soon as practicable after
the conclusion of the AGM.

 

Non-Executive Board Refreshment

As reported previously, in accordance with the 2018 UK Corporate Governance
Code the Group is implementing a plan to refresh the Non-Executive members of
its Board, which began in 2020 and is expected to complete in 2023.

 

Having appointed Grahame Cook and Douglas Le Fort as Non-Executive Directors
in 2021, Penny Freer is due to retire from the Board at the upcoming AGM. It
is expected that Douglas Le Fort will become Chair of the Remuneration
Committee, having worked closely with Penny since he joined the Remuneration
Committee in 2021. The Board would like to thank Penny for her significant
contribution to the success of AMS over the last twelve years.

 

 

- End -

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole  AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                           Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made three acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAQKLFLLZLZBBX